Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study

Basit Öğe Kaydı
dc.contributor.authorCanbaz, Hayri
dc.contributor.authorIdiz, Ufuk Ofuz
dc.contributor.authorDal, Hayriye Cankar
dc.contributor.authorKaciroglu, Fatih
dc.contributor.authorTas, Seher
dc.contributor.authorCubukcu, Hikmet Can
dc.contributor.authorBestemir, Attila
dc.date.accessioned2024-02-23T14:38:20Z
dc.date.available2024-02-23T14:38:20Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC) therapy, which is one of those methods. The aim of our study is to evaluate the effect of MSC treatment applied together with standard treatments on survival. Materials and Methods: This retrospective case-control study evaluates the survival effect of MSC treatment administered to patients treated in intensive care after the development of ARDS due to COVID-19 between March 2020 and March 2021. The age, gender, comorbid disease status, APACHE II score, and overall and comorbidity-based survival rates were compared between patients who received standard medical treatment (SMT) and patients who received MSC treatment together with SMT. Results: There were 62 patients in the group receiving only SMT and 81 patients in the group receiving SMT and MSC. No difference was observed between the groups in terms of age, gender, presence of comorbid diseases, or APACHE II scores. There were also no differences according to Kaplan-Maier analysis for the survival statuses of the groups. There was no serious adverse effect due to MSC treatment among these patients. Conclusion: Our study presents the largest case series in the literature, and it was observed that MSC treatment may not significantly affect overall survival or comorbid disease-based survival, in contrast to many other studies in the literature.en_US
dc.identifier.doi10.4274/tjh.galenos.2022.2022.0103
dc.identifier.endpage229en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.pmid36250478en_US
dc.identifier.scopus2-s2.0-85143088554en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage222en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2022.2022.0103
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16452
dc.identifier.volume39en_US
dc.identifier.wosWOS:000968447700001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid-19en_US
dc.subjectMesenchymal Stem Cellen_US
dc.subjectEmergencyen_US
dc.subjectMortalityen_US
dc.subjectSurvivalen_US
dc.titleEffectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu